Literature DB >> 1781100

Accuracy of magnetic resonance imaging compared to computerized tomography and renal selective angiography in preoperatively staging renal cell carcinoma.

C Constantinides1, F Recker, W Bruehlmann, G von Schulthess, N Goebel, C Zollikofer, P Jaeger, D Hauri.   

Abstract

During 1986 and 1987, 47 patients with renal cell carcinoma were evaluated preoperatively with CT, angiography and MRI. The preoperative tumor stage (T), lymph node metastases and venous involvement determined with the three methods were compared to the operative and histopathological findings. For T stage, angiography proved less accurate (54%) than CT (64%) or MRI (63%). MRI was found to be superior to CT in assessing lymph nodes, with an overall accuracy of 89% and sensitivity of 100% compared to 77 and 60%, respectively, of CT. For venous involvement CT was overall more accurate (74%) than angiography (65%) or MRI (63%). All three methods expressed a low sensitivity (between 31 and 41%) and a high specificity (between 95 and 100%) for detecting venous involvement. The minimal advantages of MRI compared to its high cost do not justify its routine use. CT remains the method of choice in staging preoperatively renal cell carcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 1781100     DOI: 10.1159/000282219

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Renal cell carcinoma with level 2 IVC thrombus.

Authors:  Samarth Agarwal; Ram Niwas Yadav; Gaurav Garg; Manoj Kumar
Journal:  BMJ Case Rep       Date:  2018-07-05

Review 2.  Preoperative imaging in renal cell cancer.

Authors:  Axel Heidenreich; Vincent Ravery
Journal:  World J Urol       Date:  2004-07-30       Impact factor: 4.226

3.  Renal Cell Carcinoma with IVC Thrombi; Current Concepts and Future Perspectives.

Authors:  Mohammed Ahmed Abdel-Muneem Nouh; Masashi Inui; Yoshiyuki Kakehi
Journal:  Clin Med Oncol       Date:  2008-03-26

Review 4.  Assessing lymph node status in patients with kidney cancer.

Authors:  Ashkan Tadayoni; Anna K Paschall; Ashkan A Malayeri
Journal:  Transl Androl Urol       Date:  2018-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.